BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2677628)

  • 1. Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.
    Buckley JD; Lampkin BC; Nesbit ME; Bernstein ID; Feig SA; Kersey JH; Piomelli S; Kim T; Hammond GD
    Med Pediatr Oncol; 1989; 17(5):382-90. PubMed ID: 2677628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
    Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F
    Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
    [No Abstract]   [Full Text] [Related]  

  • 9. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive treatment of acute leukemia in adults 70 years of age and older.
    Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
    Ravindranath Y; Steuber CP; Krischer J; Civin CI; Ducore J; Vega R; Pitel P; Inoue S; Bleher E; Sexauer C
    J Clin Oncol; 1991 Apr; 9(4):572-80. PubMed ID: 2066754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
    Liang R; Chiu E; Chan TK; Todd D
    Cancer Chemother Pharmacol; 1990; 26(5):380-2. PubMed ID: 2208581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
    Pavlovsky S; Fernández I; Palau V; Santarelli MT; De Bellis R; Ruiz-Argüelles G; Brandalise S; Jiménez-Fonseca E
    Ann Oncol; 1991 Jun; 2(6):441-2. PubMed ID: 1768631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
    Amadori S; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Covelli A; Mandelli F
    J Clin Oncol; 1987 Sep; 5(9):1356-63. PubMed ID: 3476689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.